Evidence map›Paper›PMID 39810535›Full record

ArticleMicroRNA (Shariqah, United Arab Emirates)2025

micro-RNA 451-a as a Circulating Biomarker for Neuroblastoma.

Aditya Kumar Gupta, Aijaz Ahmad, Disha Kakker, Jagdish Prasad Meena, Ravi Kumar Majhi, Ambreen Jan, Rachna Seth, Venkatesawaran Iyer, Saumyaranjan Mallick

Abstract read
PubMed Publisher
In one paragraph

Article in MicroRNA (Shariqah, United Arab Emirates), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aditya Kumar GuptaDepartment of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India.
Aijaz AhmadDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Disha KakkerDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Jagdish Prasad MeenaDepartment of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India.
Ravi Kumar MajhiDepartment of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India.
Ambreen JanDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Rachna SethDepartment of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India.
Venkatesawaran IyerDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Saumyaranjan MallickDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.

Funding

AIIMS, New Delhi Intramural Research, India F.5-59/IRG/2010/RS
6 · The paper itself

Abstract

introductionMicro ribonucleic acids (miRNAs) are small non-coding RNAs that modulate the expression of various genes. They have an important role in cancer pathogenesis. Differential expression of multiple miRNAs have been used as potential diagnostic and prognostic markers.

methodsVarious miRNAs have lately been employed as diagnostic and therapeutic targets in different cancers. This prospective study included untreated pediatric neuroblastoma (NB) patients. In the discovery phase, global miRNA profiling was done using next-generation sequencing (NGS) on biopsy tissue samples of NB patients. In this phase, the top expressing miRNAs were identified and chosen for further validation as circulating miRNA in blood samples of a different set of NB patients by real-time polymerase chain reaction (PCR).

resultsBased on the read counts on the global miRNA profiling in the discovery phase, we found that the miRNA that consistently had high reads across the majority of the NB samples were miRNA 451-a, 19b-3p, 106b-5p, and 21-5p. Of these, we selected miRNA 451-a and 19-b for the validation phase of the study as they had consistent overexpression. In the validation phase, the expression of the circulating miRNA 451-a in the blood was found to be higher. The average value for the relative fold (RF) expression for miRNA 451-a was 1.52.

conclusionmiRNA 451-a is overexpressed both in the cancer tissue and the blood of NB patients. It can serve as a potential diagnostic marker. Further studies can elucidate its role in the pathogenesis of NB and it could have utility as a therapeutic target.

Indexed as

Biomarkers, TumorCirculating MicroRNAMicroRNAsNeuroblastomaChildChild, PreschoolFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansInfantMaleProspective StudiesBiomarkers, TumorCirculating MicroRNAMicroRNAsbiomarkercirculatingmiRNA 451-aneuroblastomanext-generation sequencing.

Identifiers

PMID39810535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.